Pacira Pharmaceuticals buy Needham & Company LLC
Start price
01.03.24
/
50%
€26.80
Target price
01.03.25
€41.61
Performance (%)
-6.72%
Price
06.05.24
€24.40
Summary
This prediction is currently active. With a performance of -6.72%, the BUY prediction by Needham___Company_LL is trending in the wrong direction. This prediction currently runs until 01.03.25. The prediction end date can be changed by Needham___Company_LL at any time. Needham___Company_LL has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | 1.667% | 1.667% |
iShares Core DAX® | 0.476% | -0.039% |
iShares Nasdaq 100 | 1.290% | 0.504% |
iShares Nikkei 225® | 1.300% | -2.135% |
iShares S&P 500 | 0.829% | 0.193% |
Comments by Needham___Company_LL for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $45.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Needham___Company_LL for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€25.80
09.04.24
09.04.24
€41.35
09.04.25
09.04.25
-3.10%
06.05.24
06.05.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€33.40
03.08.23
03.08.23
€47.53
03.08.24
03.08.24
-25.15%
06.05.24
06.05.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€41.00
20.04.23
20.04.23
€54.71
20.04.24
20.04.24
-40.98%
21.04.24
21.04.24
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€40.40
28.02.23
28.02.23
€56.63
28.02.24
28.02.24
-32.18%
29.02.24
29.02.24